Oncology bispecific antibody trial starts vs Alzheimer's disease drug trial starts
In 2025, oncology bispecific antibody trial starts worldwide stood at 317, against 78 for alzheimer's disease drug trial starts.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Oncology bispecific antibody trial starts and Alzheimer's disease drug trial starts
Unit: count · 12 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Oncology bispecific antibody trial starts | 2025 | Actual | 317 |
| Oncology bispecific antibody trial starts | 2024 | Actual | 226 |
| Oncology bispecific antibody trial starts | 2023 | Actual | 189 |
| Oncology bispecific antibody trial starts | 2022 | Actual | 130 |
| Oncology bispecific antibody trial starts | 2021 | Actual | 104 |
| Oncology bispecific antibody trial starts | 2020 | Actual | 61 |
| Alzheimer's disease drug trial starts | 2025 | Actual | 78 |
| Alzheimer's disease drug trial starts | 2024 | Actual | 71 |
| Alzheimer's disease drug trial starts | 2023 | Actual | 58 |
| Alzheimer's disease drug trial starts | 2022 | Actual | 81 |
| Alzheimer's disease drug trial starts | 2021 | Actual | 87 |
| Alzheimer's disease drug trial starts | 2020 | Actual | 66 |
Shared periods
Side by side
6 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.
| Period | Oncology bispecific antibody trial starts | Alzheimer's disease drug trial starts |
|---|---|---|
| 2020 | 61 ClinicalTrials.gov | 66 ClinicalTrials.gov |
| 2021 | 104 ClinicalTrials.gov | 87 ClinicalTrials.gov |
| 2022 | 130 ClinicalTrials.gov | 81 ClinicalTrials.gov |
| 2023 | 189 ClinicalTrials.gov | 58 ClinicalTrials.gov |
| 2024 | 226 ClinicalTrials.gov | 71 ClinicalTrials.gov |
| 2025 | 317 ClinicalTrials.gov | 78 ClinicalTrials.gov |
Provenance
Where these numbers come from
Oncology bispecific antibody trial starts
Count of interventional oncology studies whose record mentions a bispecific antibody by class or by name (ivonescimab, cadonilimab, pumitamig, T-cell engagers such as teclistamab and tarlatamab, and others) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Alzheimer's disease drug trial starts
Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring